Chronic inflammation drives much of the disease activity and symptoms in both MPNs and MDS
Even modest differences in percentage weight loss can influence long-term outcomes, particularly in patients with obesity-related conditions
Clinical evidence supporting weight loss Clinical trials show the effectiveness of semaglutide for weight loss
Liraglutide (Victoza, Saxenda) Approved for obesity at higher doses, typically results in 57% weight loss
This gives patients greater flexibility when discussing treatment goals with their healthcare provider
To mitigate this, low-adsorption flow paths, such as low adsorption columns and system components, are increasingly used to minimize peptide-surface interactions, improve recovery, and enhance overall method sensitivity and accuracy